ArticlePloS one2013
Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- No association between acid suppressant use and risk of dementia: an updated meta-analysis.European journal of clinical pharmacology · 2022Pooled it
- Association of Proton Pump Inhibitor Use With Incident Dementia and Cognitive Decline in Older Adults: A Prospective Cohort Study.Gastroenterology · 2023Trial
- A Bioactive Fraction of Euphorbia antiquorum Stem Powder Ameliorates High-Fat High-Fructose Diet/Streptozotocin-Induced Diabetes via GLUT-4 Modulation.Chemistry & biodiversity · 2026Article
- Helicobacter pylori promotes hepatocarcinogenesis by abrogating the protective effect of intestinal Bacteroides acidifaciens in females.Journal of translational medicine · 2026Article
- EGF and GHRP6 Co-Administration Attenuates Cognitive Decline in Preclinical Models: Behavioral and Molecular Evidences.Neurotoxicity research · 2026Article
- Causal relationship between proton pump inhibitors and dementia risk: evidence from a Mendelian randomization study.European archives of psychiatry and clinical neuroscience · 2025Article
- Myeloperoxidase as a therapeutic target for oxidative damage in Alzheimer's disease.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Modulation of the cognitive impairment associated with Alzheimer's disease by valproic acid: possible drug repurposing.Inflammopharmacology · 2025Article
- Association between proton pump inhibitors and dementia risk: a Mendelian randomization study.Scientific reports · 2024Article
- Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates.Frontiers in aging neuroscience · 2024Article
- Bergenin ameliorates cognitive deficits and neuropathological alterations in sodium azide-induced experimental dementia.Frontiers in pharmacology · 2022Article
- Quercetin Exhibits α7nAChR/Nrf2/HO-1-Mediated Neuroprotection Against STZ-Induced Mitochondrial Toxicity and Cognitive Impairments in Experimental Rodents.Neurotoxicity research · 2021Article
- Favorable effects of dill tablets andIranian journal of basic medical sciences · 2021Article
- Article
- Time-course study of high fat diet induced alterations in spatial memory, hippocampal JNK, P38, ERK and Akt activity.Metabolic brain disease · 2019Article
- Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis.Drug safety · 2018Article
- Proton Pump Inhibitor Use and Dementia Risk: Prospective Population-Based Study.Journal of the American Geriatrics Society · 2018Article
- Global loss of acetylcholinesterase activity with mitochondrial complexes inhibition and inflammation in brain of hypercholesterolemic mice.Scientific reports · 2017Article
- Association Between Proton Pump Inhibitor Use and Cognitive Function in Women.Gastroenterology · 2017Article
- Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system.Naunyn-Schmiedeberg's archives of pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigates the potential of lansoprazole (a proton pump inhibitor and agonist of liver x receptors) in experimental dementia of AD type. Streptozotocin [STZ, 3 mg/kg, injected intracerebroventricular (i.c.v), and high fat diet (HFD, administered for 90 days)] were used to induce dementia in separate groups of Swiss mice. Morris water maze (MWM) test was performed to assess learning and memory of the animals. A battery of biochemical and histopathological studies were also performed. Extent of oxidative stress was measured by estimating the levels of brain reduced glutathione (GSH) and thiobarbituric acid reactive species (TBARS). Brain acetylcholinestrase (AChE) activity and serum cholesterol levels were also estimated. The brain level of myeloperoxidase (MPO) was measured as a marker of inflammation. STZ and HFD produced a marked decline in MWM performance of the animals, reflecting impairment of learning and memory. STZ/HFD treated mice exhibited a marked accentuation of AChE activity, TBARS and MPO levels along with a fall in GSH levels. Further, the stained micrographs of STZ/HFD treated mice indicated pathological changes, severe neutrophilic infiltration and amyloid deposition. Lansoprazole treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations. It also prevented HFD-induced rise in the cholesterol level. Therefore, the findings demonstrate potential of lansoprazole in memory dysfunctions which may probably be attributed to its anti-cholinesterase, anti-oxidative and anti-inflammatory effects. Moreover, both cholesterol-dependent as well as cholesterol-independent effects of lansoprazole appear to play a role. In addition study indicates the role of liver x receptors in dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.